Herbalife Q2 Results: Transformative Product Releases
Herbalife reported Q2 earnings in line with prior guidance. EBITDA and cash flow were healthy, consistent with recent quarters. In my view, this was a solid quarter driven primarily by sales of Herbalife’s legacy products—shakes, aloe, and teas.
Distributor trends, particularly the new distributor pool, improved year over year. While growth didn’t match the strong 2024 vs. 2023 gains, the improvement was still positive. North America was slightly negative and remains a critical territory to watch as Herbalife rolls out key innovations in the coming quarters.
Pro2col App Beta Release
Key Highlights from Q2 centered on product developments that set the tone for what’s ahead. Herbalife launched the beta version of its Pro2col digital wellness app, bundled with a new metabolic health supplement. Pro2col is envisioned to be the single destination for biomarker and health data, dietary and physical activity goal tracking, and coaching/community engagement.
Metabolic Health Supplement
The metabolic health supplement taps into the latest trends in metabolic support and vitamin metabolization. Two notable active ingredients—Methylcobalamin and methyl folate—are more bioavailable forms of B-vitamins, particularly important for the 20–40% of Americans with gene markers indicating some level of impaired B-vitamin processing.
Together, the Pro2col beta launch and metabolic health supplement represent some of Herbalife’s most significant product innovation in years—expanding beyond its core protein shakes into broader wellness and personalized nutrition.
Multi-Burn
Herbalife also introduced Multi-Burn, a pill based weight-loss supplement formulated with botanical extracts such as Morosil (blood orange) and Capsifen (red pepper), designed for improved absorption. This non-pharmaceutical weight management option caters to those seeking weight loss support without prescription GLP medications.
Wrap-Up
Taken together, these late-Q2 product launches signal a new era for Herbalife: a shift from a protein-shake-dominated lineup toward a holistic portfolio that supports a healthy lifestyle and personalized wellness.
Looking ahead, my focus will remain on the North American market, where these new products are debuting first. Q4 will be especially important as the full version of Pro2col rolls out to North American distributors.
It was a solid quarter, my outlook remains unchanged, and the valuation continues to look compelling. For deeper background, see my original Herbalife write-ups. I remain bullish.
Disclaimer: I am not a registered investment advisor. This article is for informational purposes only and should not be considered investment advice. The opinions expressed are my own and are based on publicly available information. Investors should conduct their own research before making any investment decisions. I may hold positions in the securities mentioned, and I have no obligation to update or notify of any changes to those positions.